Vimseltinib
- Generic Name
- Vimseltinib
- Drug Type
- Small Molecule
- Chemical Formula
- C23H25N7O2
- CAS Number
- 1628606-05-2
- Unique Ingredient Identifier
- PX9FTM69BF
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06619561
- Locations
- ๐บ๐ธ
City of Hope National Medical Center, Duarte, California, United States
๐บ๐ธRonald Regan UCLA Medical Center, Los Angeles, California, United States
๐บ๐ธAdventHealth Orlando, Orlando, Florida, United States
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
Phase 3
Active, not recruiting
- Conditions
- Tenosynovial Giant Cell Tumor, DiffuseTenosynovial Giant Cell TumorPigmented Villonodular SynovitisTenosynovial Giant Cell Tumor, LocalizedGiant Cell Tumor of Tendon Sheath
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 123
- Registration Number
- NCT05059262
- Locations
- ๐ช๐ธ
Hospital Universitario Vall d'Hebron, Barcelona, Spain
๐บ๐ธOhio State University, Columbus, Ohio, United States
๐บ๐ธUniversity of Colorado, Aurora, Colorado, United States
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
Phase 1
Active, not recruiting
- Conditions
- SarcomaAdvanced SarcomaHigh Grade SarcomaLeiomyosarcomaUndifferentiated Pleomorphic SarcomaMyxofibrosarcomaDedifferentiated Liposarcoma
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT04242238
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Phase 1
Active, not recruiting
- Conditions
- Giant Cell Tumor of Tendon SheathTenosynovial Giant Cell Tumor, DiffuseAdvanced Malignant NeoplasmTenosynovial Giant Cell TumorPigmented Villonodular Synovitis
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT03069469
- Locations
- ๐บ๐ธ
Stanford Cancer Institute, Palo Alto, California, United States
๐บ๐ธMSKCC, New York, New York, United States
๐ฆ๐บPeter MacCallum Cancer Centre, Melbourne, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath